公司資料
Nkarta 股價、新聞與催化劑
- 股票代碼:
- NKTX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.43 USD (+4.29%)
收盤價
最後更新: 2026年8月17日
208M USD
市值
股價為何變動
As of Aug 17, 2026, NKTX closed up 4.29% at $2.43. No new same-company headline was identified in the current news window.
公司概覽
Allogeneic CAR-NK Company
Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer.
NKX019
NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing.
Ntrust Studies
Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with outpatient dosing and the option for redosing.
未來催化劑
- Initial clinical data from the Ntrust-1 and Ntrust-2 studies of NKX019 at a medical conference in 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。